$ASRT Not a bad call. They don't have their heads in the sand. Focus is to deliver debt and boost EBITDA. They will save 20 MM in 2020 by eliminating contract sales force. They are not on the opioid litigators' radars and have been dropped from 17 legal cases. They can meet their debt obligations. Nucynta sales were a little soft.
  • 2
  • 1